Numeco, an affiliate of Medytox, said on the 15th that its botulinum toxin product "NewLux" received marketing authorization from Bolivia's drug and medical device registration agency (AGEMED). The company noted that Bolivia is a market with strong interest in cosmetic procedures.
NewLux improved production yield and quality through a latest process. In the process of producing the bulk substance, it excluded animal-derived ingredients to eliminate the possibility of allergic reactions caused by animal antigens. Previously, NewLux was approved in Peru, Thailand, and Georgia.
A Numeco official said, "We will aggressively target the local market to raise brand recognition."
※ This article has been translated by AI. Share your feedback here.